Bruker to Provide 60 Explosives Trace Detectors for Zuerich Airport
16 Agosto 2023 - 5:05PM
Business Wire
Largest Swiss Airport to Enhance Passenger
and Airport Security with high-performance Bruker DE-tector™ Flex
(Drugs & Explosives Detector) Systems in 2024-2025
Bruker Corporation today announced that Flughafen Zürich AG in
Switzerland has ordered 60 Bruker DE-tector flex
explosives and narcotics trace detectors to support their airport
security measures. The installations are planned over a 24-month
period in 2024 and 2025 to enhance the screening of passengers at
Switzerland’s busiest airport. The next-generation,
high-performance Bruker DE-tector flex systems are intended to
replace earlier explosive trace detectors (ETD) at Zuerich Airport.
First-generation Bruker ETD detectors are already deployed at
Geneva Airport in Switzerland.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230816348984/en/
Bruker explosives and narcotics trace
detector DE-tector flex
The Bruker DE-tector flex is a next-generation
transportable explosives and narcotics trace detector that meets
the requirements of two important security applications in
airports. By wiping surfaces with multi-use, disposable swabs, and
inserting them into the DE-tector flex, traces of two
classes of explosive and narcotics substances can be identified
automatically within seconds. The new DE-tector flex system
is certified by ECAC (European Civil Aviation Conference) and
utilizes a non-radioactive ionization source.
Dr. Andreas Kamlowski, President of the Bruker Optics Division,
stated: “We are very pleased to have been selected for the
next-generation security project at Zuerich Airport to provide
innovative technologies and solutions that support the safety and
security of the public and the aviation industry.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230816348984/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 313-5800 E: Investor.Relations@bruker.com
Media Contact: Michael Mueller Marketing Manager Bruker
Optics Division T: +49 7243 504 2652
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024